Neurodome Secures Tens of Millions in Series A Funding to Advance Non-Invasive Deep Brain Neuromodulation

Recently, Neurodome, Inc. (hereinafter referred to as "Neurodome"), an innovator focusing on non-invasive deep brain neuromodulation technology, has successfully completed a multi-million yuan Series A financing round. This round of financing was jointly led by Huafang Capital and iFlytek Ventures, with Heping Capital participating as a follower.

This round of financing will help the company accelerate the continuous exploration and development of Temporal Interference (TI) technology in the field of brain science, promote multi-scenario product solutions, and advance clinical registration, product certification, and commercialization for various indications.

Neurodome always regards clinical needs as the guiding principle, efficiently advancing clinical exploration and industrial implementation based on TI technology. Among its achievements, the TI Research Edition product, only one year after its release, has already established collaborations with nearly a hundred top clinical centers and university research institutions both in China and internationally. It has cumulatively conducted over a thousand TI research clinical cases across dozens of indications, including depression, Parkinson’s disease, essential tremor, sleep disorders, post-traumatic stress disorder, and epilepsy, achieving inspiring interim clinical results. Its progress is leading globally, providing a new option for non-invasive deep brain neuromodulation in neuroscience and psychiatric disorders.